Overlapping genes in Nalp6/PYPAF5 locus encode two V2-type vasopressin isoreceptors: Angiotensin-vasopressin receptor (AVR) and non-AVR

Physiological Genomics

Volumn 34, Issue 1, 2008, Pages 65-77

  Herrera, Victoria L M ^a   Bagamasbad, Pia ^a   Didishvili, Tamara ^a   Decano, Julius L ^a   Ruiz Opazo, Nelson ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen; Signaling pathway; Testosterone; Vasopressin sexual diergism

Indexed keywords

ADENYLATE CYCLASE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN VASOPRESSIN RECEPTOR; ESTROGEN; MESSENGER RNA; TESTOSTERONE; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR; ISOPROTEIN; LIGAND; NALP6 PROTEIN, RAT; PEPTIDE; SEX HORMONE; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

5' UNTRANSLATED REGION; AMINO TERMINAL SEQUENCE; ANDROGEN RESPONSE ELEMENT; ARTICLE; AVR GENE; CELL STRAIN COS1; CELLULAR DISTRIBUTION; ESTROGEN RESPONSIVE ELEMENT; FLUID BALANCE; GENE; GENE MAPPING; GENOME ANALYSIS; HORMONE RESPONSIVE ELEMENT; MOLECULAR SIZE; NALP6 GENE; NAVR GENE; PRIORITY JOURNAL; PROMOTER REGION; PYPAF5 GENE; RECEPTOR AFFINITY; RECEPTOR GENE; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SODIUM URINE LEVEL; TISSUE SECTION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; ANTIBODY SPECIFICITY; CERCOPITHECUS; CONFOCAL MICROSCOPY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; GENOME; METABOLISM; PROTEIN BINDING; RAT; TRANSCRIPTION INITIATION SITE; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; COS CELLS; GENE EXPRESSION REGULATION; GENOME; GONADAL STEROID HORMONES; LIGANDS; MICROSCOPY, CONFOCAL; ORGAN SPECIFICITY; PEPTIDES; PROTEIN BINDING; PROTEIN ISOFORMS; RATS; RECEPTORS, ANGIOTENSIN; RECEPTORS, VASOPRESSIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC; TRANSFECTION; VASOPRESSINS;

EID: 47249152815     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00199.2007     Document Type: Article

References (55)

1. i-dependent mechanism. Am J Physiol Renal Physiol 294: F345-F354, 2008.
2. Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51: 1184-1190, 2002.
3. Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol (January 17, 2008). doi:10.1210/me.2007-0529.
4. Albrecht M, Domingues FS, Schreiber S, Lengauer T. Identification of mammalian orthologs associates PYPAF5 with distinct functional roles. FEBS Lett 538: 173-177, 2003.
5. Burnatowska-Hledin MA, Spielman WS, Smith WL, Shi P, Meyer JM, Dewitt DL. Expression cloning of an AVP-activated, calcium-mobilizing receptor from rabbit kidney medulla. Am J Physiol Renal Fluid Electrolyte Physiol 268: F1198-F1210, 1995.
6. Chan SM, Ermann J, Su L, Fathman CG, Utz PJ. Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 10: 1390-1396, 2004.
7. Chen BS, Hampsey M. Transcription activation: unveiling the essential nature of TFIID. Curr Biol 12: R620-R622, 2002.
8. Condorelli G, Vigliotta G, Iavarone C, Caruso M, Tocchetti CG, Andreozzi F, Cafieri A, Tecce MF, Formisano P, Beguinot L, Beghinot F. PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J 17: 3858-3866, 1998.
9. Dulin NO, Niu J, Browning DD, Ye RD, Voyno-Yasenetskaya T. Cyclic AMP-independent activation of protein kinase A by vasoactive peptides. J Biol Chem 276: 20827-20830, 2001.
10. Evans R, Fairley JA, Roberts SGE. Activator-mediated disruption of sequence-specific DNA contacts by the general transcription factor TFIIB. Genes Dev 15: 2945-2949, 2001.
11. Folli F, Saad MJA, Velloso L, Hansen H, Carandente O, Feener EP, Khan CR. Crosstalk between insulin and angiotensin II signaling systems. Exp Clin Endocrinol Diabetes 107: 133-139, 1999.
12. Fukue Y, Sumida N, Nishikawa J, Ohyama T. Core promoter elements of eukaryotic genes have a highly distinctive mechanical property. Nucleic Acids Res 32: 5834-5840, 2004.
13. Gerhold D, Bagchi A, Lu M, Figueroa D, Keenan K, Holder D, Wang Y, Jin H, Connolly B, Austin C, Alonso-Galicia M. Androgens drive divergent responses to salt stress in male versus female rat kidneys. Genomics 89: 731-744, 2007.
14. Gobinet J, Poujol N, Sultan C. Molecular action of androgens. Mol Cell Endocrinol 198: 15-24, 2002.
15. Gonzalez CB, Herrera VLM, Ruiz-Opazo N. Renal immunocytochemical distribution and pharmacological properties of the dual angiotensin II/AVP receptor. Hypertension 29: 957-961, 1997.
16. 2+ responses in isolated rat supraoptic neurons. J Physiol 517: 771-779, 1999.
17. Grenier JM, Wang L, Manji GA, Huang WJ, Al-Garawi A, Kelly R, Carlson A, Merriam S, Lora JM, Briskin M, DiStefano PS, Bertin J. Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-κB and caspase-1. FEBS Lett 530: 73-78, 2002.
18. 2-adrenergic receptor impairs agonist activation of adenylyl cyclase without affecting high affinity agonist binding. Distinct molecular determinants of the receptor are involved in physical coupling to and functional activation of GS. J Biol Chem 265: 1388-1393, 1990.
19. Herrera VLM, Ruiz-Opazo N. Regulation of -tropomyosin and N5 genes by a shared enhancer: modular structure and hierarchical organization. J Biol Chem 265: 9555-9562, 1990.
20. Herrera VLM, Makrides SC, Xie HX, Adari H, Kraus RM, Ryan US, Ruiz-Opazo N. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med 5: 1383-1389, 1999.
21. Herrera VL, Ruiz-Opazo N. Identification of a novel V1-type AVP receptor based on the molecular recognition theory. Mol Med 7: 499-506, 2001.
22. HS hypertensive rats. Physiol Genomics 26: 172-179, 2006.
23. Higashiyama M, Ishikawa S, Saito T, Nakamura T, Kusaka I, Nagasaka S, Honda K, Saito T. Arginine vasopressin inhibits apoptosis of rat glomerular mesangial cells via V1a receptors. Life Sci 68: 1485-1493, 2001.
24. Hurbin A, Boissin-Agasse L, Orcel H, Rabie A, Joux N, Desarmenien MG, Richard P, Moos FC. The V1a and V1b, but not V2, vasopressin receptor genes are expressed in the supraoptic nucleus of the rat hypothalamus, and the transcripts are essentially colocalized in the vasopressinergic magnocellular neurons. Endocrinology 139: 4701-4707, 1998.
25. Hurbin A, Orcel H, Ferraz C, Moos FC, Rabie A. Expression of the genes encoding the vasopressin-activated calcium-mobilizing receptor and the dual angiotensin II/vasopressin receptor in the rat central nervous system. J Neuroendocrinol 12: 677-684, 2000.
26. +)-ATPase: active site determinations and criteria of purity. Ann NY Acad Sci 242: 36-52, 1974.
27. Kailong L, Du X, Yani H, Lin Z, Jvrong Y, Ruihua S, Lin C. P53-Rb signaling pathway is involved in tubular cell senescence in renal ischemia/reperfusion injury. Biocell 31: 213-223, 2007.
28. Kaneko Y, Herrera VLM, Didishvili T, Ruiz-Opazo N. Sex-specific effects of dual ET-1/ANG II receptor (Dear) variants in Dahl salt-sensitive/resistant hypertension rat model. Physiol Genomics 20: 157-164, 2005.
29. Kaufmann J, Smale ST. Direct recognition of initiator elements by a component of the transcription factor IID complex. Genes Dev 8: 821-829, 1994.
30. Kiley SC, Thornhill BA, Tang SS, Ingelfinger JR, Chevalier RL. Growth factor-mediated phosphorylation of proapoptotic BAD reduces tubule cell death in vitro and in vivo. Kidney Int 63: 33-42, 2003.
31. Klein JP, Hains BC, Craner MJ, Black JA, Waxman SG. Apoptosis of vasopressinergic hypothalamic neurons in chronic diabetes mellitus. Neurobiol Dis 15: 221-228, 2004.
32. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29: 2905-2919, 2001.
33. Kuratsune M, Masaki T, Hirai T, Kiribayashi K, Yokoyama Y, Arakawa T, Yorioka N, Kohno N. Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction. Nephrology (Carlton) 12: 565-571, 2007.
34. Kutach AK, Kadonaga JT. The downstream promoter element DPE appears to be as widely used as the TATA box in Drosophila core promoters. Mol Cell Biol 20: 4754-4764, 2000.
35. Landry JR, Mager DL, Wilhelm BT. Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet 19: 640-648, 2003.
36. Li R, Yang N, Zhang L, Huang Y, Zhang R, Wang F, Luo M, Liang Y, Yu X. Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome. Am J Nephrol 27: 580-589, 2007.
37. Makalowska I, Lin CF, Makaloski W. Overlapping genes in vertebrate genomes. Comput Biol Chem 29: 1-12, 2005.
38. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 290: F762-F768, 2006.
39. Nielsen S, Frokler J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82: 205-244, 2002.
40. Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc Natl Acad Sci USA 100: 9330-9335, 2003.
41. Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, Meijer L, Nelson PJ. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int 73: 684-690, 2008.
42. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling-in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371, 2006.
43. Pearson H. What is a gene? Nature 441: 399-401, 2006.
44. -- cotransporter (hkNBCe1). Am J Physiol Renal Physiol 290: F417-F427, 2006.
45. Rhodes ME, Rubin RT. Functional sex differences ("sexual diergism") of central nervous system cholinergic systems, vasopressin, and hypothalamic-pituitary-adrenal axis activity in mammals: a selective review. Brain Res Rev 30: 135-152, 1999.
46. Rodbard D. Mathematics of hormone-receptor interaction. I. Basic principles. Adv Exp Med Biol 36: 289-326, 1973.
47. Ruiz-Opazo N, Akimoto K, Herrera VLM. Identification of a novel dual angiotensin II/vasopressin receptor on the basis of molecular recognition theory. Nat Med 1: 1074-1081, 1995.
48. Ruiz-Opazo N, Lopez LV, Herrera VLM. The dual Ang II/AVP receptor gene N119S/C163R variant exhibits sodium-induced dysfunction and cosegregates with salt-sensitive hypertension in the Dahl salt-sensitive hypertensive rat model. Mol Med 8: 24-32, 2002.
49. Sabatier N, Shibuya I, Dayanithi G. Intracellular calcium increase and somatodendritic vasopressin release by vasopressin receptor agonists in the rat supraoptic nucleus: involvement of multiple transduction signals. J Neuroendocrinol 16: 221-236, 2004.
50. Shi YH, Zhao S, Wang C, Li Y, Duan HJ. Fluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditions. Acta Pharmacol Sin 28: 1938-1946, 2007.
51. Szolkiewicz M, Sucajtys E, Wolyniec W, Rutkowski P, Stelmanska E, Korczynska J, Swierczynski J, Rutkowski B. Mechanisms of enhanced carbohydrate and lipid metabolism in adipose tissue in uremia. J Ren Nutr 15: 166-172, 2005.
52. Szutorisz H, Dillon N, Tora L. The role of enhancers as centers for general transcription factor recruitment. Trends Biochem Sci 30: 593-599, 2005.
53. Veeramachaneni V, Makalowski W, Galdzicki M, Sood R, Makalowska I. Mammalian overlapping genes: the comparative perspective. Genome Res 14: 280-286, 2006.
54. Wang Y, Ji HX, Xing SH, Pei DS, Guan QH. SP600125, a selective JNK inhibitor, protects ischemic renal injury via suppressing the extrinsic pathways of apoptosis. Life Sci 80: 2067-2075, 2007.
55. Woo SK, Lee SD, Kwon HM. TonEBP transcriptional activator in the cellular response to increased osmolality. Pflügers Arch 444: 579-585, 2002.